Circio Holding ASA Company Profile, Contacts & Intelligence

Circio Holding ASA Overview

Circio Holding ASA is a clinical stage company developing immune activators to target difficult-to-treat diseases. The company’s mission is to deploy vector-based technology to create a novel class of targeted, multi-functional circRNA medicines. It has established a cutting-edge circular RNA (circRNA) program and is collaborating with Prof Michael Uhlin and a team at the Karolinska Institutet in Stockholm with the intent to develop next generation RNA therapeutics for various applications. The company also has a mutant RAS cancer vaccine program, with two collaborative clinical trials underway in the USA and Norway. It is currently looking at options for the financing of a phase 2 study for ONCOS-102, a genetically modified oncolytic adenovirus.

Headquarters

Oslo, No

Website

targovax.com

Industry

Biotechnology Research

Founded

2010

NAICS

Research and Development in Biotechnology (except Nanobiotechnology)

Circio Holding ASA Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

Circio Holding ASA People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

Circio Holding ASA Workforce Composition

Seniority breakdown across 3 visible profiles.

Compare Similar Companies to Circio Holding ASA

Explore companies in related markets and compare their industry and employee estimates.